,41,43, 44, 45 While future work should investigate the utility of artARENA vector technology for prophylactic antibody induction against infectious diseases, potent CD8 T cell responses position heterologous artARENA vector prime-boost immunization as a promising strategy for therapeutic vaccination in persistent microbial diseases, notably HIV and hepatitis B.7,82. This evidence concerns the gene CD8A and hepatitis B virus infection.